Company: AIBT
Filing Date: 2025-07-03
Form Type: 253G2
Source: 0001096906-25-001087
Chunk: 38

Company: AIBOTICS, INC.
Filing Date: 2025-07-03
Form: 253G2
Chunk 38
---
 incorporated on December 22, 1994. On March 26, 2014, we amended and restated our articles of incorporation to increase our authorized shares of common stock to 100,000,000 shares, par value $0.001, and to authorize 5,000,000 shares of preferred stock, par value $0.001. In connection with this reorganization, we obtained a new CUSIP number for our common stock, FINRA approval of our name change from RM Investors, Inc. to 20/20 Global, Inc., and a new trading symbol for our shares on the OTC marketplace and effected a 2-for-1 forward split of the then issued and outstanding shares of our common stock. In December 2020, we entered into definitive agreements with Ehave, Inc., an Ontario corporation, Mycotopia Therapies Inc., a Florida corporation and wholly owned subsidiary of Ehave, Inc., and the former and current directors of 20/20 Global that provide for the 20/20 Global’s purchase of all of the outstanding stock of Mycotopia Therapies, Inc. from Ehave, Inc. In May 2021, we changed our name to Mycotopia Therapies Inc. On August 9, 2024, we increased our authorized Common shares to 467,000,000 common shares. On February 3, 2025, we changed our name to Aibotics, Inc. and our trading symbol to AIBT. On March 14, 2025, the Company’s board approved an increase in the company’s common shares to 7,500,000,000. We have two subsidiaries, Mycotopia Therapies Inc., a Florida corporation, and NPD Genius, LLC, a Florida limited liability company. Our board of directors consists of Ben Kaplan and Mark Croskey. AIBotics leverages AI and robotics to develop innovative solutions that address real-world challenges. Its flagship products include the Phill Robot™, an AI-powered massage robot that delivers spa-quality care with IoT integration, and Milkyway, a smart refrigerator that simplifies breast milk storage with automated organization and app connectivity. References to “us,” “we,” “our,” and correlative terms refer to Aibotics, Inc. and our wholly owned subsidiary, NPD Genius, LLC, a Florida limited liability company and Mycotopia Therapies, Inc., a Florida corporation, through which we conducted our activities. 28 Business Strategy and